Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FROVA vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Acute treatment of migraine with or without aura in adults
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
2.5 mg orally once daily; maximum 5 mg/day.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life is 26 hours. This prolonged half-life supports once-daily dosing and provides sustained headache relief.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Hepatic via CYP1A2; primary metabolite is 5-hydroxyfrovatriptan.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic metabolism followed by renal and fecal elimination. Approximately 62% of the dose is recovered in urine (mainly as metabolites, <10% unchanged) and 32% in feces.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Approximately 15% bound to plasma proteins (primarily albumin).
92-98% bound to plasma proteins (primarily albumin)
Volume of distribution (Vd) is approximately 2.4 L/kg, indicating extensive tissue distribution.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral bioavailability is approximately 30% due to first-pass metabolism.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No adjustment required for GFR ≥30 m L/min; use not recommended for GFR <30 m L/min.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Contraindicated in severe hepatic impairment (Child-Pugh C); use with caution in moderate impairment (Child-Pugh B) at reduced dose (2.5 mg every other day).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not approved for use in pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment, but monitor for increased sensitivity and renal function due to age-related decline.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
Do not use in patients with ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular conditions.
No FDA black box warning.
Risk of myocardial ischemia, cerebral hemorrhage, cardiac arrhythmias; serotonin syndrome with concomitant serotonergic drugs; medication overuse headache; severe hepatic impairment.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Ischemic heart disease, coronary artery vasospasm, history of stroke/TIA, peripheral vascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, recent MAOI use, hypersensitivity.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
No significant food interactions. Grapefruit juice does not affect frovatriptan metabolism. Avoid alcohol during migraine attacks as it may worsen headache or increase drowsiness.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Frovatriptan is contraindicated in pregnancy due to potential fetal harm. In animal studies, frovatriptan was associated with reduced fetal weights and increased incidence of fetal abnormalities at maternal toxic doses. In humans, there is no adequate data; however, triptans as a class may increase risk of preterm delivery, low birth weight, and possibly orofacial clefts when used in the first trimester. Use during first trimester: Risk category not formally assigned but should be avoided. Second and third trimesters: Avoid due to potential for uterine contractions and reduced placental perfusion. Labor and delivery: Contraindicated as it may cause uterine hypertonicity and fetal distress.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Frovatriptan is excreted into breast milk in low amounts; the M/P ratio is approximately 2.6:1 (milk to plasma ratio). The relative infant dose is estimated at 1.5-3.5% of the maternal weight-adjusted dose. While adverse effects in breastfed infants have not been reported, caution is advised due to potential for vasoconstriction and gastrointestinal disturbances. Consider pumping and discarding milk for 24 hours after dose.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, hepatic metabolism alterations) may reduce frovatriptan exposure. However, due to contraindication and lack of safety data, no adjusted dosing is recommended. Use in pregnancy is not advised; alternative medications with better safety profiles (e.g., sumatriptan) should be considered if triptan therapy is necessary.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Frovatriptan has the longest half-life (~26 hours) among triptans, which may be beneficial for patients with prolonged migraine attacks or frequent recurrence. Onset of action is slower (~2-4 hours) compared to sumatriptan. Use with caution in patients with cardiovascular risk factors due to vasoconstrictive effects. Contraindicated within 24 hours of other triptans or ergotamine-containing medications.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take FROVA at the first sign of a migraine headache, but it can be taken any time during an attack.,Do not exceed one tablet (2.5 mg) in a 24-hour period; if headache returns, repeat dose after at least 2 hours.,Do not take within 24 hours of another triptan or ergotamine-type medication.,Common side effects include dizziness, fatigue, tingling, and flushing. Report chest tightness, palpitations, or shortness of breath immediately.,Seek emergency care if headache worsens or is accompanied by stiff neck, fever, or vision changes.,Inform your doctor if you have heart disease, high blood pressure, liver disease, or are pregnant or breastfeeding.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
"Frovatriptan, a serotonin 5-HT1B/1D receptor agonist used for acute migraine, and chlorpromazine, a first-generation antipsychotic with potent dopamine D2 receptor antagonism, can lead to additive serotonin excess when co-administered due to their combined serotonergic activity. Chlorpromazine also possesses weak serotonin reuptake inhibition properties, increasing the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Additionally, chlorpromazine may antagonize the vasoconstrictive effects of triptans via alpha-adrenergic blockade, potentially reducing migraine relief efficacy."
"Frovatriptan, a triptan used for migraine, is primarily metabolized by CYP1A2. Clotrimazole, an azole antifungal, inhibits CYP1A2, thereby reducing the clearance of frovatriptan. This can lead to increased systemic exposure to frovatriptan, potentially elevating the risk of triptan-related adverse effects such as serotonin syndrome, coronary vasospasm, and hypertension."
"Coadministration of frovatriptan, a serotonin receptor agonist metabolized primarily by CYP1A2, with simeprevir, a potent CYP3A4 inhibitor and weak CYP1A2 inducer, may result in reduced clearance of simeprevir due to competitive inhibition of CYP3A4 by frovatriptan or its metabolites. This interaction can lead to increased simeprevir plasma concentrations, elevating the risk of hepatotoxicity, photosensitivity reactions, and QT prolongation. Conversely, frovatriptan exposure is not significantly altered as its metabolism via CYP1A2 is minimally affected by simeprevir."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FROVA vs AFEDITAB CR, answered by our medical review team.
FROVA is a Antimigraine (triptan) that works by Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FROVA and AFEDITAB CR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FROVA is: 2.5 mg orally once daily; maximum 5 mg/day.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FROVA and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FROVA is classified as Category C. Frovatriptan is contraindicated in pregnancy due to potential fetal harm. In animal studies, frovatriptan was associated with reduced fetal weights and increased incidence of fetal. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.